BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 507.08 Million SEK | 8.99% |
| 2022 | 467.26 Million SEK | 37.29% |
| 2021 | 340.35 Million SEK | 12.95% |
| 2020 | 301.34 Million SEK | -4.03% |
| 2019 | 313.98 Million SEK | 11.94% |
| 2018 | 280.5 Million SEK | 24.74% |
| 2017 | 224.87 Million SEK | 16.64% |
| 2016 | 192.79 Million SEK | 3.62% |
| 2015 | 186.06 Million SEK | 15.36% |
| 2014 | 161.29 Million SEK | 20.09% |
| 2013 | 134.3 Million SEK | 6.11% |
| 2012 | 126.57 Million SEK | 11.61% |
| 2011 | 113.41 Million SEK | 10.52% |
| 2010 | 102.61 Million SEK | 17.19% |
| 2009 | 87.56 Million SEK | 31.55% |
| 2008 | 66.56 Million SEK | 6.37% |
| 2007 | 62.57 Million SEK | 8.94% |
| 2006 | 57.44 Million SEK | -3.3% |
| 2005 | 59.4 Million SEK | 1591.36% |
| 2004 | -3.98 Million SEK | -59.64% |
| 2003 | -2.49 Million SEK | 89.62% |
| 2002 | -24.03 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 247.2 Million SEK | 81.48% |
| 2024 Q2 | 142.85 Million SEK | -42.21% |
| 2024 Q3 | 180.91 Million SEK | 26.64% |
| 2023 FY | 509.28 Million SEK | 8.99% |
| 2023 Q2 | 131.4 Million SEK | 14.75% |
| 2023 Q1 | 114.51 Million SEK | -30.03% |
| 2023 Q4 | 136.21 Million SEK | 17.12% |
| 2023 Q3 | 116.3 Million SEK | -11.49% |
| 2022 Q2 | 104.64 Million SEK | -2.12% |
| 2022 Q3 | 92.04 Million SEK | -12.04% |
| 2022 FY | 467.26 Million SEK | 37.29% |
| 2022 Q1 | 106.91 Million SEK | 0.92% |
| 2022 Q4 | 163.65 Million SEK | 77.8% |
| 2021 Q4 | 105.94 Million SEK | 74.57% |
| 2021 FY | 340.35 Million SEK | 12.95% |
| 2021 Q1 | 80.95 Million SEK | -14.53% |
| 2021 Q2 | 81.62 Million SEK | 0.83% |
| 2021 Q3 | 60.68 Million SEK | -25.65% |
| 2020 Q4 | 94.71 Million SEK | 51.64% |
| 2020 Q1 | 77.38 Million SEK | -1.52% |
| 2020 Q2 | 84.2 Million SEK | 8.81% |
| 2020 Q3 | 62.46 Million SEK | -25.82% |
| 2020 FY | 301.34 Million SEK | -4.03% |
| 2019 Q3 | 72.51 Million SEK | -14.61% |
| 2019 FY | 313.98 Million SEK | 11.94% |
| 2019 Q1 | 77.97 Million SEK | -6.02% |
| 2019 Q4 | 78.57 Million SEK | 8.36% |
| 2019 Q2 | 84.92 Million SEK | 8.91% |
| 2018 Q2 | 76.42 Million SEK | 38.37% |
| 2018 Q4 | 82.96 Million SEK | 25.95% |
| 2018 FY | 280.5 Million SEK | 24.74% |
| 2018 Q1 | 55.23 Million SEK | -20.44% |
| 2018 Q3 | 65.87 Million SEK | -13.81% |
| 2017 Q1 | 48.48 Million SEK | -15.17% |
| 2017 Q4 | 69.42 Million SEK | 36.18% |
| 2017 Q3 | 50.97 Million SEK | -8.95% |
| 2017 FY | 224.87 Million SEK | 16.64% |
| 2017 Q2 | 55.99 Million SEK | 15.48% |
| 2016 Q4 | 57.15 Million SEK | 24.09% |
| 2016 Q2 | 47.25 Million SEK | 11.66% |
| 2016 Q1 | 42.32 Million SEK | -4.97% |
| 2016 FY | 192.79 Million SEK | 3.62% |
| 2016 Q3 | 46.06 Million SEK | -2.52% |
| 2015 Q1 | 48.56 Million SEK | -1.46% |
| 2015 FY | 186.06 Million SEK | 15.36% |
| 2015 Q4 | 44.53 Million SEK | 0.95% |
| 2015 Q3 | 44.11 Million SEK | -9.71% |
| 2015 Q2 | 48.85 Million SEK | 0.61% |
| 2014 Q2 | 41.84 Million SEK | 22.68% |
| 2014 Q3 | 36.06 Million SEK | -13.82% |
| 2014 Q4 | 49.28 Million SEK | 36.66% |
| 2014 Q1 | 34.1 Million SEK | -5.8% |
| 2014 FY | 161.29 Million SEK | 20.09% |
| 2013 FY | 134.3 Million SEK | 6.11% |
| 2013 Q2 | 36.01 Million SEK | 8.93% |
| 2013 Q4 | 36.2 Million SEK | 24.77% |
| 2013 Q3 | 29.02 Million SEK | -19.42% |
| 2013 Q1 | 33.06 Million SEK | -7.42% |
| 2012 Q4 | 35.71 Million SEK | 19.61% |
| 2012 Q3 | 29.85 Million SEK | -14.06% |
| 2012 Q2 | 34.74 Million SEK | 110.64% |
| 2012 Q1 | -326.55 Million SEK | -1110.2% |
| 2012 FY | 126.57 Million SEK | 11.61% |
| 2011 Q4 | 32.32 Million SEK | 25.71% |
| 2011 Q1 | 25.13 Million SEK | -3.54% |
| 2011 Q2 | 28.78 Million SEK | 14.52% |
| 2011 Q3 | 25.71 Million SEK | -10.66% |
| 2011 FY | 113.41 Million SEK | 10.52% |
| 2010 Q1 | 25.19 Million SEK | 5.53% |
| 2010 Q3 | 23.73 Million SEK | -11.24% |
| 2010 FY | 102.61 Million SEK | 17.19% |
| 2010 Q2 | 26.74 Million SEK | 6.13% |
| 2010 Q4 | 26.05 Million SEK | 9.77% |
| 2009 Q2 | 21.48 Million SEK | -2.71% |
| 2009 Q1 | 22.07 Million SEK | 0.0% |
| 2009 FY | 87.56 Million SEK | 31.55% |
| 2009 Q4 | 23.87 Million SEK | 18.09% |
| 2009 Q3 | 20.21 Million SEK | -5.88% |
| 2008 Q2 | 18.17 Million SEK | 0.0% |
| 2008 FY | 66.56 Million SEK | 6.37% |
| 2007 FY | 62.57 Million SEK | 8.94% |
| 2006 FY | 57.44 Million SEK | -3.3% |
| 2005 FY | 59.4 Million SEK | 1591.36% |
| 2004 FY | -3.98 Million SEK | -59.64% |
| 2003 FY | -2.49 Million SEK | 89.62% |
| 2002 FY | -24.03 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -3727.353% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -1225.299% |
| Enzymatica AB (publ) | 79.92 Million SEK | -534.452% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -1226.547% |
| Gabather AB (publ) | 9.47 Million SEK | -5252.396% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -3306.92% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -1746.433% |
| Nanexa AB (publ) | 135.78 Million SEK | -273.456% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -1584.056% |
| ODI Pharma AB | -5.00 SEK | 10141720100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 23.099% |
| Probi AB (publ) | 208.93 Million SEK | -142.703% |
| Swedencare AB (publ) | 1.12 Billion SEK | 55.038% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 94.604% |
| Toleranzia AB | 6.97 Million SEK | -7173.178% |
| Vivesto AB | 355.71 Million SEK | -42.553% |